Q32 Bio Capital Expenditures (CapEx) Growth & History (QTTB)
Q32 Bio's capital expenditures (capex) was $0 for fiscal 2025.
View full Q32 Bio company overviewQ32 Bio annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $0 | −$75,000 | — |
| 2024 | 2024-12-31 | $75,000 | $70,000 | +1400.00% |
| 2023 | 2023-12-31 | $5,000 | −$1.3M | −99.61% |
| 2022 | 2022-12-31 | $1.3M | −$1.1M | −46.37% |
| 2021 | 2021-12-31 | $2.4M | −$1.3M | −35.82% |
| 2020 | 2020-12-31 | $3.7M | −$18.1M | −82.90% |
| 2019 | 2019-12-31 | $21.8M | −$3.1M | −12.45% |
| 2018 | 2018-12-31 | $24.9M | $23.0M | +1173.70% |
| 2017 | 2017-12-31 | $2.0M | — | — |
Q32 Bio quarterly capital expenditures (capex)
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q3 2025 | 2025-09-30 | $0 | −$58,000 | — |
| Q4 2024 | 2024-12-31 | $2,000 | $2,000 | — |
| Q3 2024 | 2024-09-30 | $58,000 | $57,000 | +5700.00% |
| Q2 2024 | 2024-06-30 | $15,000 | $14,000 | +1400.00% |
| Q1 2024 | 2024-03-31 | $0 | −$5,000 | — |
| Q4 2023 | 2023-12-31 | $0 | −$9,000 | — |
| Q3 2023 | 2023-09-30 | $1,000 | −$5,000 | −83.33% |
| Q2 2023 | 2023-06-30 | $1,000 | −$120,000 | −99.17% |
| Q1 2023 | 2023-03-31 | $5,000 | −$1.1M | −99.56% |
| Q4 2022 | 2022-12-31 | $9,000 | −$329,000 | −97.34% |
| Q3 2022 | 2022-09-30 | $6,000 | −$471,000 | −98.74% |
| Q2 2022 | 2022-06-30 | $121,000 | −$643,000 | −84.16% |
| Q1 2022 | 2022-03-31 | $1.1M | $332,000 | +40.64% |
| Q4 2021 | 2021-12-31 | $338,000 | −$617,000 | −64.61% |
| Q3 2021 | 2021-09-30 | $477,000 | $320,000 | +203.82% |
| Q2 2021 | 2021-06-30 | $764,000 | $176,000 | +29.93% |
| Q1 2021 | 2021-03-31 | $817,000 | −$1.2M | −59.81% |
| Q4 2020 | 2020-12-31 | $955,000 | −$2.8M | −74.36% |
| Q3 2020 | 2020-09-30 | $157,000 | −$1.6M | −90.89% |
| Q2 2020 | 2020-06-30 | $588,000 | −$5.3M | −90.07% |
| Q1 2020 | 2020-03-31 | $2.0M | −$8.4M | −80.58% |
| Q4 2019 | 2019-12-31 | $3.7M | −$12.2M | −76.62% |
| Q3 2019 | 2019-09-30 | $1.7M | −$3.1M | −64.29% |
| Q2 2019 | 2019-06-30 | $5.9M | $2.8M | +87.96% |
| Q1 2019 | 2019-03-31 | $10.5M | $9.4M | +911.21% |
| Q4 2018 | 2018-12-31 | $15.9M | $15.6M | +4630.72% |
| Q3 2018 | 2018-09-30 | $4.8M | $4.5M | +1510.81% |
| Q2 2018 | 2018-06-30 | $3.1M | $2.7M | +565.34% |
| Q1 2018 | 2018-03-31 | $1.0M | $186,567 | +21.99% |
| Q4 2017 | 2017-12-31 | $336,735 | — | — |
| Q3 2017 | 2017-09-30 | $299,538 | — | — |
| Q2 2017 | 2017-06-30 | $473,294 | — | — |
| Q1 2017 | 2017-03-31 | $848,433 | — | — |
Q32 Bio capital expenditures (capex) trends
Over the last five fiscal years, Q32 Bio's capital expenditures (capex) decreased from $3.7M to $0, a change of −$3.7M. The latest reported quarter, Q3 2025, shows $0.
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Q32 Bio source filings ↗